| Iron in chronic brain disorders: imaging and neurotherapeutic implications J Stankiewicz, SS Panter, M Neema, A Arora, CE Batt, R Bakshi Neurotherapeutics 4 (3), 371-386, 2007 | 364 | 2007 |
| A probiotic modulates the microbiome and immunity in multiple sclerosis SK Tankou, K Regev, BC Healy, E Tjon, L Laghi, LM Cox, P Kivisäkk, ... Annals of neurology 83 (6), 1147-1161, 2018 | 210 | 2018 |
| T1‐and T2‐based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis M Neema, J Stankiewicz, A Arora, VSR Dandamudi, CE Batt, ZD Guss, ... Journal of Neuroimaging 17, 16S-21S, 2007 | 153 | 2007 |
| Brain MRI lesion load at 1.5 T and 3T versus clinical status in multiple sclerosis JM Stankiewicz, BI Glanz, BC Healy, A Arora, M Neema, RHB Benedict, ... Journal of Neuroimaging 21 (2), e50-e56, 2011 | 145 | 2011 |
| Investigation of probiotics in multiple sclerosis SK Tankou, K Regev, BC Healy, LM Cox, E Tjon, P Kivisakk, IP Vanande, ... Multiple Sclerosis Journal 24 (1), 58-63, 2018 | 135 | 2018 |
| Role of iron in neurotoxicity: a cause for concern in the elderly? JM Stankiewicz, SD Brass Current Opinion in Clinical Nutrition & Metabolic Care 12 (1), 22-29, 2009 | 113 | 2009 |
| The relationships among MRI‐defined spinal cord involvement, brain involvement, and disability in multiple sclerosis AB Cohen, M Neema, A Arora, E Dell’Oglio, RHB Benedict, S Tauhid, ... Journal of Neuroimaging 22 (2), 122-128, 2012 | 111 | 2012 |
| MRI in multiple sclerosis: what’s inside the toolbox? M Neema, J Stankiewicz, A Arora, ZD Guss, R Bakshi Neurotherapeutics 4 (4), 602-617, 2007 | 111 | 2007 |
| Iron and multiple sclerosis JM Stankiewicz, M Neema, A Ceccarelli Neurobiology of aging 35, S51-S58, 2014 | 108 | 2014 |
| Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study JM Stankiewicz, M Neema, DC Alsop, BC Healy, A Arora, GJ Buckle, ... Journal of the neurological sciences 279 (1-2), 99-105, 2009 | 100 | 2009 |
| An argument for broad use of high efficacy treatments in early multiple sclerosis JM Stankiewicz, HL Weiner Neurology: Neuroimmunology & Neuroinflammation 7 (1), e636, 2019 | 87 | 2019 |
| Normal findings on brain fluid-attenuated inversion recovery MR images at 3T M Neema, ZD Guss, JM Stankiewicz, A Arora, BC Healy, R Bakshi American Journal of Neuroradiology 30 (5), 911-916, 2009 | 79 | 2009 |
| COVID-19 in teriflunomide-treated patients with multiple sclerosis AH Maghzi, MK Houtchens, P Preziosa, C Ionete, BD Beretich, ... Journal of neurology 267, 2790-2796, 2020 | 76 | 2020 |
| Role of immunosuppressive therapy for the treatment of multiple sclerosis JM Stankiewicz, H Kolb, A Karni, HL Weiner Neurotherapeutics 10 (1), 77-88, 2013 | 62 | 2013 |
| Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale R Bakshi, M Neema, BC Healy, Z Liptak, RA Betensky, GJ Buckle, ... Archives of neurology 65 (11), 1449-1453, 2008 | 62 | 2008 |
| A 3T MR imaging investigation of the topography of whole spinal cord atrophy in multiple sclerosis JP Klein, A Arora, M Neema, BC Healy, S Tauhid, D Goldberg-Zimring, ... American journal of neuroradiology 32 (6), 1138-1142, 2011 | 61 | 2011 |
| Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate M Baharnoori, J Lyons, A Dastagir, I Koralnik, JM Stankiewicz Neurology: Neuroimmunology & Neuroinflammation 3 (5), e274, 2016 | 55 | 2016 |
| A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity F Esposito, M Sorosina, L Ottoboni, ET Lim, JM Replogle, T Raj, ... Annals of neurology 78 (1), 115-127, 2015 | 50 | 2015 |
| Levetiracetam for seizures after liver transplantation GA Glass, J Stankiewicz, A Mithoefer, R Freeman, PR Bergethon Neurology 64 (6), 1084-1085, 2005 | 46 | 2005 |
| Multiple sclerosis: diagnosis and therapy HL Weiner, JM Stankiewicz John Wiley & Sons, 2012 | 44 | 2012 |
